SIX •
Healthcare •
Biotechnology •
Quote as of 09/08/2026 17:31
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeSIX
Market Capitalization1,370.65 mln
Float149 mln
Earnings Date10/29/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-4.61
Highly reliable
Relative Strength
1
/ 100
Severely lagging
Debt / Equity
-1.11
Negative equity
Pre-Tax Margin
-157%
Severely loss-making
Dividend Yield
0.00%
No dividend
Business Description
Idorsia is a Swiss biopharmaceutical company focused on researching and bringing to market new medicines that address conditions with few or no existing treatment options, including sleep disorders, heart and immune system conditions, and rare diseases. Its leading product, QUVIVIQ, is an approved treatment for insomnia, while several other potential therapies are at various stages of clinical testing across areas such as skin conditions, neurological disorders, and organ injury. The company operates across multiple major markets, including the United States, Japan, China, and Europe. Founded in 2017 and based in Allschwil, Switzerland, Idorsia also works alongside partners such as Janssen Biotech and Viatris to develop and commercialize additional treatments.
